EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SGLT2 inhibitors in nephrolithiasis: a paradigm shift in prevention and management

Marco Lombardi, Stefano Michelassi, Silverio Rotondi

Giornale di Clinica Nefrologica e Dialisi · 18.05.2026 · 38 (1) · 89-99

DOI: 10.33393/gcnd.2026.3760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Giornale di Clinica Nefrologica e Dialisi, online erschienen am 18.05.2026. Verfasst von Marco Lombardi und 2 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney stone disease (nephrolithiasis) is a prevalent, recurrent condition often underpinned by modifiable metabolic risk factors such as hypocitraturia, hyperuricosuria, and low urinary pH. Although prevention through dietary and pharmacologic interventions is possible, it remains inconsistently applied in clinical practice. Sodium–glucose co-transporter 2 inhibitors (SGLT2i), originally developed for glycemic control in type 2 diabetes, have shown unexpected effects on renal metabolism and acid-base handling, prompting interest in their potential utility in stone prevention. SGLT2i promotes glycosuria and shift in acid–base balance, which may increase urinary citrate and pH—both protective against stone formation. They also reduce serum uric acid and may exert favorable effects on urinary volume and calcium handling. These mechanisms suggest a growing therapeutic role in selected patients with nephrolithiasis, especially those with comorbid diabetes, chronic kidney disease (CKD), or hypocitraturia. While direct clinical data on stone recurrence under SGLT2i therapy are still limited, mechanistic consistency across preclinical and clinical studies is compelling. SGLT2 inhibitors are thus emerging as a promising pharmacologic strategy for nephrolithiasis prevention, particularly in patients with overlapping metabolic or renal indications. Ongoing mechanistic studies and prospective trials are expected to confirm their role as part ofa personalized approach to stone disease management.

Zitieren

APA

Lombardi, M., Michelassi, S., & Rotondi, S. (2026). SGLT2 inhibitors in nephrolithiasis: a paradigm shift in prevention and management. Giornale di Clinica Nefrologica e Dialisi, 38(1), 89-99. https://doi.org/10.33393/gcnd.2026.3760

Vancouver

Lombardi M, Michelassi S, Rotondi S. SGLT2 inhibitors in nephrolithiasis: a paradigm shift in prevention and management. Giornale di Clinica Nefrologica e Dialisi. 2026;38(1):89-99. doi:10.33393/gcnd.2026.3760

BibTeX
@article{Lombardi2026,
  author = {Lombardi, Marco and Michelassi, Stefano and Rotondi, Silverio},
  title = {SGLT2 inhibitors in nephrolithiasis: a paradigm shift in prevention and management},
  journal = {Giornale di Clinica Nefrologica e Dialisi},
  year = {2026},
  volume = {38},
  number = {1},
  pages = {89--99},
  doi = {10.33393/gcnd.2026.3760}
}
Kostenlos starten →